---
title: "Skills & Prompts"
description: "Paste-ready prompts and packaged skills that turn Amass into finished analyst work in Claude, Codex, Copilot, or any MCP-compatible assistant. Each carries a real, validated answer and downloadable take-home files."
url: https://amass.tech/skills
---

# Skills & Prompts

Skills & Prompts

# Run Amass in any assistant

Paste-ready prompts and packaged skills that turn Amass into finished analyst work in Claude, Codex, Copilot, or any MCP-compatible assistant. Each carries a real, validated answer and downloadable take-home files, and needs no build or deploy.

[Connect Amass via MCP](https://amass.tech/mcp)

Topic

Mode

Output

13 items

[

pdf+1

196trials in scope

competitive-intelligenceSkillFeatured

## Landscape Monitor

Name a field; get it mapped across trials, papers, patents, drugs, genes and approvals into a landscape page with charts, a workbook and a one-page briefing, every record screened with its reason. Ask for an update later to see what is new and what changed.

Open showcase

](https://amass.tech/skills/amass-landscape-monitor)

[

xlsx

14trials watched

| Short name | Source id | Registry | Copy of |
| --- | --- | --- | --- |
| Acute, 50/75 mg vs placebo | NCT04072354 | ClinicalTrials.gov |  |
|  | ↳ EUCTR2019-000470-36-BG | EU CTR | NCT04072354 |
| Acute, 75/100 mg vs placebo | NCT04092686 | ClinicalTrials.gov |  |

competitive-intelligenceSkill

### Watchlist Monitor

Name the trials, papers, approvals or drugs you need to follow; get one Excel board that re-reads them through Amass at every check and tells you exactly what changed: status, dates, enrollment, results posted, label revisions, retractions, new links.

](https://amass.tech/skills/amass-watchlist-monitor)[

csv

12targets scored

| kinase | kinase\_family\_chembl\_leaf | small\_molecule\_tractability | protac\_tractability |
| --- | --- | --- | --- |
| PLK1 | Other protein kinase PLK family | Advanced Clinical | predictive-only |
| WEE1 | Other protein kinase WEE family | Advanced Clinical | predictive-only |
| CDK1 | CMGC protein kinase CDK5 subfamily | Advanced Clinical | predictive-only |

researchSkill

### Target prioritization matrix

A general, interview-driven target-discovery workbench: name the biology and the modality you care about, and get back a scored table of candidate targets — druggability, essentiality, genetic constraint, curated safety, and the real number of drugs already targeting each — assembled from GeneCore intelligence and DrugCore/TrialCore/BiomedCore/PatentCore cross-links.

](https://amass.tech/skills/target-prioritization-matrix)[

csv

2approved, first-gen

| record\_type | title | id | source |
| --- | --- | --- | --- |
| paper | Mechanisms of Resistance to KRASG12C Inhibitors | PMID:33466360 | Cancers (JuFo 2) |
| paper | Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges | PMID:34607583 | Molecular Cancer (JuFo 3) |
| paper | KRAS G12C Mutations in NSCLC: From Target to Resistance | PMID:34064232 | Cancers (JuFo 2) |

competitive-intelligenceSkill

### Biomedical Evidence Scout

Name a drug, target, mechanism, or indication; get a landscape briefing that maps the published literature AND the clinical pipeline together — every paper and trial carrying a real Amass ID, PMID, or NCT you can check.

](https://amass.tech/skills/amass-biomedical-evidence-scout)[

csv+1

7linked papers

| rank | title | journal | publicationDate |
| --- | --- | --- | --- |
| 1 | Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | The New England journal of medicine | 2022-02-10 |
| 2 | Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial | JAMA network open | 2023-04-03 |
| 3 | Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial | medRxiv (preprint) | 2022-09-21 |

clinical-evidenceSkill

### Trial evidence trace

Paste one clinical-trial ID; get the exact published papers that describe it — pulled from Amass's publication↔trial graph, with trust metadata and abstract-grounded relevance notes.

](https://amass.tech/skills/trial-evidence-trace)[

docx

5Phase-3 trials

1\. Pivotal Phase-3 program

AMASS EVIDENCE BRIEF

regulatoryPrompt

### Tirzepatide evidence brief

Name a drug asset; get a citation-auditable Word evidence brief — pivotal Phase-3 trials, grounded efficacy and safety findings, and the trial↔paper links — every figure verbatim from Amass.

](https://amass.tech/skills/tirzepatide-evidence-brief)[

docx+1

6Phase-3 trials

EXPLORER-HCM - NCT03470545 (16 describing papers)

Submission Evidence Assembler - mavacamten (Camzyos)

regulatorySkill

### Submission evidence assembler

Name one drug asset; get a citation-auditable, Module-2.5-style evidence narrative — every pivotal Phase-3 trial, its describing papers, and a canonical Amass-ID audit trail — assembled from Amass's publication↔trial graph with trust metadata on every cited paper.

](https://amass.tech/skills/submission-evidence-assembler)[

pdf

2MAESTRO trials

researchPrompt

### Resmetirom evidence snapshot

Name a drug asset; get a one-page PDF evidence snapshot — regulatory status, pivotal trials, grounded efficacy figures and the trial↔paper link — every number verbatim from Amass.

](https://amass.tech/skills/resmetirom-evidence-snapshot)[

csv+1

10papers screened

| PMID | AMBC | title | journal |
| --- | --- | --- | --- |
| 25037936 | AMBC\_LgGUu4qEoXy99ZBBdZt6kLYpaq9 | Modeling and research on research | Clinical chemistry |
| 29534060 | AMBC\_VRlhiy7cmm9d5q13WjyMr2UA9I0 | Meta-research: Why research on research matters | PLoS biology |
| 15878467 | AMBC\_Mk6C6o15EdZyjpf9Pl1vmAoKBoz | Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials | Journal of clinical epidemiology |

research-integritySkill

### ORCID record self-verify

Paste your own ORCID; get the publication record Amass indexes under that verified identity, screened in one pass for retractions, below-peer-review journals, and trial linkage — a clean integrity self-audit before a grant, tenure, or promotion submission.

](https://amass.tech/skills/orcid-record-self-verify)[

xlsx

10papers

| KOL paper-trial triangulator — Mikhail Kosiborod · query "cardiometabolic heart failure" |  |  |  |
| --- | --- | --- | --- |
| Top-10 by relevance (sample, not the full oeuvre). Source: Amass BiomedCore authorNames seed + per-paper referencesTrialCore edge. 6/10 trial-linked, 4/10 (meta-analyses/reviews) none. 0 retracted. |  |  |  |
| paper\_PMID | paper\_AMBC | title | journal |
| 35228754 | AMBC\_7BiZMrt83VZHgdVwEesrmHqQ0MB | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (EMPULSE) | Nature medicine |

researchSkill

### KOL paper-trial triangulator

Name a KOL plus a context query; get their top-10 most relevant papers, each triangulated to the exact clinical trial it reports — pulled from Amass's publication↔trial graph, with trust metadata and a downloadable engagement-dossier workbook.

](https://amass.tech/skills/kol-paper-trial-triangulator)[

xlsx

18Phase-3 trials

| NCT | acronym | drug (interventionNames) | sponsor |
| --- | --- | --- | --- |
| NCT01051219 | FELINE | Losartan | Newcastle-upon-Tyne Hospitals NHS Trust |
| NCT03053050 | STELLAR-3 | SEL; Placebo to match SEL 6 mg; Placebo to match SEL 18 mg | Gilead Sciences |
| NCT03900429 | MAESTRO-NASH | MGL-3196; Placebo; Liver Biopsy | Madrigal Pharmaceuticals, Inc. |

competitive-intelligenceSkill

### Indication pipeline landscape

Name one indication; get its current Phase-3 drug pipeline mapped across every sponsor — each program tagged novel-agent vs repurposed-generic and overlaid with a cross-core publication-evidence maturity count — in one downloadable Excel matrix.

](https://amass.tech/skills/indication-pipeline-landscape)[

csv+1

9claims checked

Lecanemab is FDA-approved for early Alzheimer's disease. In its 18-month phase-3 trial it delayed cognitive and functional decline by ≈5 months versus…

clinical-evidencePrompt

### Trust-filtered grounded answer

Ask a clinical question; get an answer where every sentence is pinned to a high-quality, non-retracted paper — and anything the evidence can't support is refused, not fabricated.

](https://amass.tech/skills/trust-filtered-answer)[

csv+1

10retracted papers

| rank | title | journal | year |
| --- | --- | --- | --- |
| 1 | A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine | Journal of translational medicine | 2021 |
| 2 | Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis | Journal of translational medicine | 2017 |
| 3 | Glioma gene therapy using induced pluripotent stem cell derived neural stem cells | Molecular pharmaceutics | 2011 |

research-integrityPrompt

### Retraction hotspot scan

Name a research topic; get a checkable, downloadable list of the retracted papers Amass indexes on it — ranked by citation reach, with strict no-reason guardrails.

](https://amass.tech/skills/retraction-hotspot-scan)

Get started

## Bring cited evidence into your assistant.

Connect the Amass MCP once, then run any of these workflows on your own targets, with every answer traceable to source.

[Connect Amass to Claude](https://amass.tech/mcp)

Data

No training on your data

Hosting

EU-hosted, enterprise

Isolation

Tenant-isolated by architecture

Certification

ISO 27001, SOC 2, NIS2: in motion